Introduction:Basic information about CAS 681492-22-8|Delamanid, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Delamanid |
|---|
| CAS Number | 681492-22-8 | Molecular Weight | 534.484 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | 653.7±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C25H25F3N4O6 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 349.1±34.3 °C |
|---|
Names
| Name | (2R)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3H-imidazo[2,1-b][1,3]oxazole |
|---|
| Synonym | More Synonyms |
|---|
Delamanid BiologicalActivity
| Description | Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex.In vitro: inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex.[1]In in-vitro studies, delamanid shows more potent antibacterial activity against drug-susceptible and drug-resistant strains of M. tuberculosis.[2] Delamanid do not affect rifampin, pyrazinamide, and isoniazid exposure; the ethambutol AUCτ and Cmax values are about 25% higher with delamanid coadministration. [3] In vivo: Twice-daily oral dosing of delamanid at 30 mg kg-1 for 5 days resulted in sterile cures in a mouse model of VL. [4] |
|---|
| Related Catalog | Signaling Pathways >>Anti-infection >>BacterialResearch Areas >>Cancer |
|---|
| References | [1]. Sotgiu G et al. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis. Expert Rev Anti Infect Ther. 2015 Mar;13(3):305-15. [2]. Xavier AS et al. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4 [3]. Mallikaarjun S et al. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60(10):5976-85. [4]. Patterson S et al.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. Elife. 2016 May 24;5. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Boiling Point | 653.7±65.0 °C at 760 mmHg |
|---|
| Molecular Formula | C25H25F3N4O6 |
|---|
| Molecular Weight | 534.484 |
|---|
| Flash Point | 349.1±34.3 °C |
|---|
| Exact Mass | 534.172607 |
|---|
| PSA | 103.80000 |
|---|
| LogP | 4.75 |
|---|
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
|---|
| Index of Refraction | 1.611 |
|---|
| InChIKey | XDAOLTSRNUSPPH-XMMPIXPASA-N |
|---|
| SMILES | CC1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1 |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| Delamanid |
| Imidazo[2,1-b]oxazole, 2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]phenoxy]methyl]-, (2R)- |
| (2R)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole |
| (2R)-2-Methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole |
| UNII-8OOT6M1PC7 |
| OPC-67683 |